| Molecular Weight | 534.4 g/mol |
|---|---|
| Molecular Formula | C23H21F7N4O3 |
| XLogP3 | 4.2 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 11 |
| Rotatable Bond Count | 6 |
| Exact Mass | 534.15018768 g/mol |
| Monoisotopic Mass | 534.15018768 g/mol |
| Topological Polar Surface Area | 75.2 A^2 |
| Heavy Atom Count | 37 |
| Formal Charge | 0 |
| Complexity | 810 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 3 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 4 | |
|---|---|
| Drug Name | Aprepitant |
| PubMed Health | Aprepitant (By mouth) |
| Drug Classes | Antiemetic |
| Drug Label | EMEND (aprepitant) is a substance P/neurokinin 1 (NK1) receptor antagonist, chemically described as 5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazol-3-one. Its empiric... |
| Active Ingredient | Aprepitant |
| Dosage Form | Capsule |
| Route | Oral |
| Strength | 125mg; 80mg; 40mg |
| Market Status | Prescription |
| Company | Sandoz |
| 2 of 4 | |
|---|---|
| Drug Name | Emend |
| PubMed Health | Aprepitant (By mouth) |
| Drug Classes | Antiemetic |
| Drug Label | EMEND (aprepitant) is a substance P/neurokinin 1 (NK1) receptor antagonist, chemically described as 5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazol-3-one. Its empiric... |
| Active Ingredient | Aprepitant; Fosaprepitant dimeglumine |
| Dosage Form | Capsule; Powder |
| Route | Intravenous; Oral |
| Strength | eq 150mg base/vial; 125mg; 80mg; 40mg |
| Market Status | Prescription |
| Company | Merck; Merck And |
| 3 of 4 | |
|---|---|
| Drug Name | Aprepitant |
| PubMed Health | Aprepitant (By mouth) |
| Drug Classes | Antiemetic |
| Drug Label | EMEND (aprepitant) is a substance P/neurokinin 1 (NK1) receptor antagonist, chemically described as 5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazol-3-one. Its empiric... |
| Active Ingredient | Aprepitant |
| Dosage Form | Capsule |
| Route | Oral |
| Strength | 125mg; 80mg; 40mg |
| Market Status | Prescription |
| Company | Sandoz |
| 4 of 4 | |
|---|---|
| Drug Name | Emend |
| PubMed Health | Aprepitant (By mouth) |
| Drug Classes | Antiemetic |
| Drug Label | EMEND (aprepitant) is a substance P/neurokinin 1 (NK1) receptor antagonist, chemically described as 5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazol-3-one. Its empiric... |
| Active Ingredient | Aprepitant; Fosaprepitant dimeglumine |
| Dosage Form | Capsule; Powder |
| Route | Intravenous; Oral |
| Strength | eq 150mg base/vial; 125mg; 80mg; 40mg |
| Market Status | Prescription |
| Company | Merck; Merck And |
